MedTrace Logo

Study of Individualized Amonafide to Treat Prostate Cancer

NCT00087854 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-04-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).

Conditions

Interventions

DRUG

Amonafide L-malate (drug)

Sponsors & Collaborators

  • Xanthus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michel Drouin, MD · Xanthus Life Sciences-Medical Monitor

  • Monique Champagne, BPharm, MSc · Xanthus Pharmaceuticals, Inc.

  • Mario Eisenberger, MD · Johns Hopkins University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00087854 on ClinicalTrials.gov